Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bushu Aims to Become No. 1 Contract Drug Maker in Japan
July 24, 2006
- Astellas to Promote Vesicare as 1st Choice OAB Treatment
July 24, 2006
- SUEVEY
July 24, 2006
- Teijin Pharma to Focus on New Drug Development in the US, Europe
July 24, 2006
- PII Study on Implanted Cardiac Assist Device Initiated
July 24, 2006
- Torrent Seeks Alliances with Japanese Companies
July 24, 2006
- Annual NHI Price Revision Would Cause Confusion: Mr Henmi of Nichibyokyo
July 24, 2006
- Sysmex America Receives Premier Pinnacle Award
July 24, 2006
- Chuikyo Discusses Frequency of NHI Drug Price Revisions
July 24, 2006
- SEMINAR
July 24, 2006
- Basic Policies 2006 Call For Enhancement of Drug Industry's Int'l Competitiveness
July 24, 2006
- SELF-MEDICATION NEWS IN BRIEF
July 24, 2006
- NEW PRODUCTS
July 24, 2006
- NEW PRODUCTS
July 24, 2006
- GENERIC NEWS IN BRIEF
July 24, 2006
- Drug Development Beyond Boundaries - Today's Global Cooperative Clinical Trials -
July 24, 2006
- Marketing Companies Must Ally to Survive: Mr Eguchi
July 17, 2006
- Japan Exchanges Opinions with Chinese Regulatory Authorities
July 17, 2006
- Ain Pharmaciez Sets Up Generic Drug Wholesaler
July 17, 2006
- REGULATORY NEWS IN BRIEF
July 17, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…